- Poster presentation
- Open Access
The effects of chronic sildenafil therapy in patients with stable systolic heart failure
© Thomas et al; licensee BioMed Central Ltd. 2007
- Published: 25 July 2007
- Erectile Dysfunction
- Pulmonary Arterial Hypertension
- Systolic Heart Failure
- Satisfaction Domain
- Minute Walk Distance
Sildenafil inhibits phosphodiesterases type 5, an enzyme that metabolizes cGMP. It is approved for the treatment of erectile dysfunction and pulmonary arterial hypertension. Early clinical studies showed a beneficial effect in endothelial dysfunction and severe systolic heart failure. The aim of this study was to examine the efficacy and tolerability of chronic sildenafil on exercise capacity and quality of life in patients with stable systolic heart failure.
In this double blind, placebo-controlled study, 31 patients were screened and 23 patients with symptomatic but stable systolic heart failure were randomized to placebo (P) or sildenafil (S). S was given in 20 mg dose three times daily for 6 weeks (W6) and then was increased to 40 mg tds for further 10 weeks (W16). The primary end-point was the change in six minute walk distance (6MWT) from baseline. The International index of erectile function (IIEF), Beck's depression inventory (BDI) and the Minnesota living with heart failure questionnaire (LHFQ) were used to assess the functional outcome.
Sildenafil was well tolerated in this group of patients. There was no significant difference in the placebo corrected 6MWT or LHFQ at week 16. However there was improvement in some functional parameters of erectile dysfunction and the Beck depression score, therefore, larger studies are warranted.
This article is published under license to BioMed Central Ltd.